Optimi Health Corp. OPTH
2.26 USD -0.25 (-9.80%)
At closeNov 10, 2026, 4:00 PM EST
2.26 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
2.24 Day range 2.53
2.11 52-week range 6.08
- YTD
- -62.91%
- 1 year
- -62.91%
News
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
globenewswire.com Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity VANCOUVER, British Columbia, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical developer and…
benzinga.com Optimi Health Completes Latest Production Batch Of Its MDMA Finished Drug Product; Proposed Phase 3 Trial Expected To Begin In 2027 The capsules were manufactured at Optimi’s GMP facility in Princeton, British Columbia, under its Health Canada Drug Establishment Licence, and are expected to supply three programs: the recently…
globenewswire.com Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia Batch sufficient to supply the proposed Canadian Phase 3 trial, a clinical trial in Israel in partnership with MAPS and a commercial export to treat PTSD in Australia Health Canada-authorized trial…
globenewswire.com Optimi Health to Present at the ThinkEquity Conference VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer…
globenewswire.com Optimi Health Appoints Melanie Pump to Board of Directors Seasoned finance executive brings more than 25 years of leadership experience across technology, digital infrastructure, software, fintech and emerging growth companies Seasoned finance executive…
defenseworld.net Optimi Health Corp. (NASDAQ:OPTH) Stock Short Interest Jumps 109.1% Optimi Health Corp. (NASDAQ: OPTH - Get Free Report) was the target of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 20,500…
benzinga.com Optimi Health Completes Production Batch Of 5mg Naturally Derived Psilocybin Capsules, Manufactured End To End At cGMP Facility In Princeton, British Columbia Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the…
globenewswire.com Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer…
globenewswire.com Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer VANCOUVER, British Columbia, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) ("Optimi" or the "Company"), a commercial-stage pharmaceutical manufacturer…
benzinga.com Elon Musk Once Said Psychedelics Could Help PTSD — Now FDA Holds Hearing as Optimi Health Advances MDMA Trial As Elon Musk touts psychedelics for mental health and the FDA holds hearings, Optimi Health (OPTH) supplies commercial MDMA & psilocybin.
benzinga.com Optimi Health Plans To Initiate A Phase 3 Clinical Trial Evaluating MDMA-Assisted Therapy For PTSD Authorized By Health Canada; Trial Is Expected To Begin In 2027 The Phase 3 clinical trial is intended to enroll up to 100 participants across multiple sites in Canada, with enrollment focused on veterans and current or former frontline workers, including…
globenewswire.com Optimi Health Expands Clinical Program with Phase 3 Trial Evaluating MDMA-Assisted Therapy for Post-Traumatic Stress Disorder Health Canada-authorized trial to evaluate efficacy and safety of two sessions of MDMA-assisted therapy in up to 100 veterans and frontline workers Health Canada-authorized trial to evaluate efficacy…- benzinga.com Optimi Health Plans To Initiate Multisite Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy For Individuals With Major Depressive Disorder In H1 2027, With Dosing Expected To Be Complete By 2027 End Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027Up to 200 participants at sites across Canada, among…
globenewswire.com Optimi Health to Initiate Phase 2 Clinical Trial Evaluating Psilocybin-Assisted Therapy for Major Depressive Disorder Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027
globenewswire.com Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated…
globenewswire.com Optimi Health Establishes Discretionary Equity Facility VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of…
prnewswire.com Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression /PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of- benzinga.com Optimi Health Exports Third Shipment Of Its 5Mg Psilocybin Product To Australia Since September 2025 The shipment included 1,000 capsules of 5mg psilocybin, which are being prescribed in Australia for treatment-resistant depression ("TRD"), an indication for which regulated patient access is…
globenewswire.com Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression Optimi's 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression. The export marks Optimi's third commercial shipment since launching the 5mg psilocybin capsules in…
benzinga.com Optimi Health Completes Production Of Two Microdose Psilocybin Finished Drug Products, Formulated At 1 Mg And 2 Mg Dosages; Products Available To Authorized Clinical Research Organizations Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studiesNew microdose formats extend Optimi's…
globenewswire.com Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's…
prnewswire.com Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial /PRNewswire/ - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of
globenewswire.com Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization…
gurufocus.com Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development PR Newswire VANCOUVER, BC,
prnewswire.com Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development /PRNewswire/ - via IBN - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer
globenewswire.com Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development Recent US executive order named ibogaine compounds among the psychedelic therapies prioritized for accelerated FDA review and expanded patient access Ibogaine is under investigation to treat PTSD,…
globenewswire.com Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia Optimi's 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United…- benzinga.com Optimi Health Prices Underwritten Public Offering Of 2.40M Common Shares At $6.25/Shr Common Shares to Trade on the Nasdaq Capital Market Under the Symbol "OPTH"VANCOUVER, BC, May 20, 2026 /CNW/ - Optimi Health Corp. (NASDAQ:OPTH) (CSE:OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a…